NCAM1 and breast carcinoma: To the best of our knowledge, this is the first study to report potential evidence for HER2 transfer from HER2+ breast cancer cells to immune cells, including CD14+ and CD56+ cells, by trogocytosis in HER2+ breast cancer patients (Additional file 2: Figure S2 and Figure 4).